Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
MedImmune (MEDI) said updated data from a Phase II trial showed that stage IV metastatic melanoma patients given Vitaxin had a one-year survival rate of 53%, compared with 42% for Vitaxin plus dacarbazine (DTIC). ...
